Endocrine Abstracts

Denosumab is a MAB currently licensed for use in treatment of osteoporosis. It is designed to inhibit RANK ligand to prevent bone breakdown by osteoclasts. Its use for treatment of malignant hypercalcaemia is still to be fully investigated.We present the case of a 71-year-old south Asian gentleman with recurrent resistant hypercalcaemia secondary to follicular non-Hodgkin’s lymphoma. Calcitriol levels were elevated which was thought to be lymphoma r...

Background: Graves’ disease and Hashimoto’s thyroiditis are the most common autoimmune thyroid conditions. Hyperthyroidism following hypothyroidism is a rare phenomenon. Hypothyroidism was once thought to be a permanent state requiring lifelong replacement therapy but we have noted that there are increasing numbers of cases which are against this postulation. We would like to report 3 cases initially diagnosed with hypothyroidism and referred to us following developm...

: We present a case of 79 year old lady who presented to hospital with symptoms of polyuria and polydipsia requiring admission for level 3 care. She reported no bowel symptoms or alcohol usage. Her past medical history showed that she suffered from T2DM, Epilepsy, Asthma, Hypertension and Chronic Kidney disease. Her biochemistry revealed a combination of Hyperglycaemia, Hypokalaemia, Hypomagnesemia, Hypophosphatemia, Hyponatremia and Hypocalcaemia. Her medications revealed no ...